What FABRX ARTIFICIAL INTELLIGENCE SL does

FABRX Artificial Intelligence S.L.U. is a Spanish start-up, headquartered in Santiago de Compostela, that operates as a 2023 spin-off from UK-based FABRX Ltd to commercialize AI-powered software for pharmaceutical 3D printing. The company sells three integrated products: M3DIMAKER STUDIO, a full pipeline for modeling, slicing, printer control and AI-based quality validation on FABRX's M3DIMAKER hardware; M3DISEEN, an AI-driven prediction engine that forecasts 3D printability, starting printing parameters and dissolution profiles of drug-excipient formulations; and M3DIFEEDBACK, a customizable phone and web application for collecting patient and caregiver feedback during clinical trials, deployable on FABRX AI cloud or customer infrastructure.

Underlying technology focuses on domain-specialized predictive models trained on pharmaceutical formulation data (particularly hot melt extrusion / FDM filaments), combined with inline sensor data (near-infrared, balance, pressure, bubble detection) for real-time quality assurance. The product suite is designed to bridge formulation development, manufacturing, and patient-side data capture within a single regulated workflow for personalized medicine.

Revenue mechanics are multi-streamed: M3DISEEN operates as a freemium academic web tool (free for research, with future commercial tiers implied); M3DIMAKER STUDIO is offered as restricted-use licensed software for healthcare with quote-based annual pricing; and M3DIFEEDBACK is delivered as custom development per clinical project. Go-to-market is enterprise field sales targeting five named segments — universities, hospitals, pharmacies, CDMOs and pharmaceutical companies — via consultation requests and conference participation. The sole disclosed funding is a 2025 CDTI INTELLIDOSE project grant of €43,145 cofinanced by NextGenerationEU and the Galicia regional government.

Name

FABRX ARTIFICIAL INTELLIGENCE SL

Legal name

FABRX ARTIFICIAL INTELLIGENCE S.L.U.

Website

https://fabrx-ai.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

FABRX AI is a Spanish spin-off that builds AI-powered software for pharmaceutical 3D printing, including printability prediction, printer control with inline quality validation, and patient feedback collection for personalized-medicine manufacturers, hospitals, pharmacies, CDMOs and academic researchers.

Ownership category

akta.pro rank

Product category

Pharmaceutical 3D Printing Software

NAICS

Software Publishers (513210)

SIC

Industrial Instruments For Measurement, Display, And Control (3823)

akta.pro primary industry

Machine Control, Firmware & Print Management (IMAAACAD)

akta.pro secondary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• Pharmaceutical 3D printing software
• AI formulation prediction
• Personalized medicine manufacturing
• Clinical trial feedback apps
• Printability prediction tools

Headquarters

HQ city

Santiago De Compostela

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. M3DISEEN (Academic): M3DISEEN is currently available for free as an academic project, suggesting a freemium model where the free version targets academic/research users with potential for commercial licensing in the future.
2. M3DIMAKER STUDIO Software Licensing: M3DIMAKER STUDIO is described as software that can be freely used for research and development or restricted for controlled use in healthcare, suggesting a licensing model with different tiers for research vs. commercial/healthcare applications.
3. Custom Application Development: The company offers custom downloadable apps for each clinical project through M3DIFEEDBACK, suggesting professional services or custom development revenue from healthcare institutions and clinical projects.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

FABRX AI develops and sells AI-powered software for pharmaceutical 3D printing of personalised medicines. Its product suite includes M3DIMAKER STUDIO for printer control and quality validation, M3DISEEN for AI-based prediction of formulation printability and dissolution, and M3DIFEEDBACK for collecting patient and caregiver feedback in clinical studies. The software is tightly integrated with FABRX Ltd's M3DIMAKER 3D printers and serves hospitals, pharmacies, CDMOs, and pharmaceutical companies.

Product overview

FABRX AI offers a suite of three integrated software products for pharmaceutical 3D printing: M3DIMAKER STUDIO provides complete printer control and quality assurance; M3DISEEN delivers AI-powered printability prediction; and M3DIFEEDBACK enables patient feedback collection for clinical studies. These products work together to enable personalized medicine manufacturing through 3D printing technology, from formulation development through patient care.

Differentiator

Problem solved

Functional benefit

Brands

• M3DIMAKER STUDIO: Complete software solution for 3D printing of medicines including features to simplify the printing process and validate printing using AI techniques. Controls M3DIMAKER printers and quality control upgrades.
• M3DISEEN
• M3DIFEEDBACK

Products and services

• M3DIMAKER STUDIO Complete software solution for 3D printing of medicines that enables 3D modeling, slicing, and printer control of M3DIMAKER pharmaceutical 3D printers. Includes inline quality-control upgrades such as in-built balance and near-infrared sensor integration, real-time pressure and bubble-formation monitoring via the SSE Laguna printhead, and a GCode library generator for validated, controlled-use printing in healthcare.
• M3DISEEN AI-driven prediction tool that forecasts 3D printability of pharmaceutical formulations. By inputting drug choice, excipients, and proportions, the tool predicts printability, suggested printing parameters, and dissolution characteristics. Uses large-scale data-driven models to predict physical properties of filaments manufactured by hot melt extrusion. Currently available online for free for academic research and limited to FDM technology.
• M3DIFEEDBACK Customisable phone application and web application system for collecting patient and parent/caregiver feedback in clinical trials. Includes patient management with code-based identification for privacy, feedback export to CSV, user account management with access restrictions, and cloud deployment options on FABRX AI cloud or customer cloud infrastructure. FABRX AI offers custom downloadable apps per clinical project.

Quantifiable outcome

• Reduces formulation development costs by predicting 3D printability before physical testing
• +2 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Partnerships

One partnership is on record.

• FABRX LtdcoreStrategic or Co-development PartnerFABRX AI is a spin-off company from FABRX Ltd, a UK-based company specializing in 3D printing of medicines. FABRX Ltd provides the hardware platform (M3DIMAKER 3D printers) that FABRX AI's software products (M3DIMAKER STUDIO) are designed to control and integrate with. This is a core strategic relationship as FABRX AI leverages FABRX Ltd's pharmaceutical 3D printing expertise and hardware for its software solutions.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Stratasys: Stratasys is a global leader in polymer 3D printing systems with solutions across healthcare, aerospace, and automotive. It is a broad incumbent providing 3D printing hardware, materials, and software stacks in overlapping verticals.
• 3D Systems: 3D Systems is a large, established additive manufacturing company with healthcare-focused 3D printing solutions including surgical planning, dental, and personalized medical devices. It is a broad incumbent in medical and pharmaceutical 3D printing.
• Materialise: Materialise is an established 3D printing software and services provider with a broad portfolio spanning medical, industrial, and consumer applications. It is comparable as a broader incumbent in 3D printing software workflows.
• Cytiva: Cytiva (formerly part of GE Healthcare Life Sciences) supplies bioprocessing and pharmaceutical manufacturing tools. It is a broad incumbent serving pharma manufacturing customers that FABRX AI also targets.
• Merck Life Science: Merck's Life Science division supplies pharma manufacturing and formulation tools, excipients, and laboratory products. It is a broad incumbent serving the pharmaceutical formulation and manufacturing customers FABRX AI addresses.

Emerging players

• Schrödinger: Schrödinger provides AI-driven computational chemistry and predictive modeling platforms for drug discovery and materials science. It is an emerging player with overlapping AI for pharmaceutical experimentation and formulation prediction.
• BenchSci: BenchSci applies AI to biomedical research and experimental reagent selection. It is an emerging player in AI for pharmaceutical experimentation that intersects with FABRX AI's experiment-optimization thesis.

Direct peers

• FABRX Ltd: FABRX Ltd is the UK-based parent company of FABRX AI and produces the M3DIMAKER pharmaceutical 3D printers that FABRX AI's software (M3DIMAKER STUDIO) is designed to control. They operate in the same pharmaceutical 3D printing space from complementary hardware and software angles.
• Aprecia Pharmaceuticals: Aprecia is the maker of Spritam (the first FDA-approved 3D printed drug) and develops ZipDose 3D printing technology for pharmaceutical manufacturing. It is a direct peer in commercial pharmaceutical 3D printed drug development and production.
• Triastek: Triastek is a China-based pharmaceutical company focused on 3D printing of medicines using proprietary Melt Extrusion Deposition (MED) technology. It is a direct competitor in pharmaceutical 3D printing formulation and manufacturing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/FabRx_3DP
• YouTubeyoutube.com/channel/UCqOZ5AheC89sUW0NicPlvcQ/videos
• Facebookfacebook.com/fabrx3dp
• LinkedInlinkedin.com/company/fabrx-ai

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FABRX ARTIFICIAL INTELLIGENCE SL